1-METHYL-4-(PIPERIDIN-4-YL)-PIPERAZINE | CAS:53617-36-0

We serve 1-METHYL-4-(PIPERIDIN-4-YL)-PIPERAZINE CAS:53617-36-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1-METHYL-4-(PIPERIDIN-4-YL)-PIPERAZINE

Chemical Name:1-METHYL-4-(PIPERIDIN-4-YL)-PIPERAZINE
CAS.NO:53617-36-0
Synonyms:1-METHYL-4-(PIPERIDIN-4-YL)-PIPERAZINE
1-Methyl-4-(4-piperidinyl)piperazine
1-Methyl-4-(piperidin-4-yl)piperazine
(1-methyl-4-piperidin-4-yl)-piperazine
1-Methyl-4-piperidin-4-yl-piperazine
 
Physical and Chemical Properties:
Density 1.0±0.1 g/cm3
Boiling Point 260.9±8.0 °C at 760 mmHg
Melting Point 53-56°C
Molecular Formula C10H21N3
Molecular Weight 183.294
Flash Point 113.9±13.1 °C
 
Specification:
Appearance:Off-white to gray solid
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Brigatinib



Contact us for information like 1-METHYL-4-(PIPERIDIN-4-YL)-PIPERAZINE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Methyl-4-piperidin-4-yl-piperazine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(1-methyl-4-piperidin-4-yl)-piperazine Use and application,1-METHYL-4-(PIPERIDIN-4-YL)-PIPERAZINE technical grade,usp/ep/jp grade.


Related News: All of China’s provinces and territories have now been touched by the outbreak.Acetic Acid 2-Chloroethyl Ester manufacturer The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.1-CYCLOPROPYL-6,7-DIFLUORO-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXYLIC ACID supplier The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.5-Chloro-2-iodopyridine vendor But they’ll be subject to up to 14 days of mandatory quarantine once they’re back in the US.But they’ll be subject to up to 14 days of mandatory quarantine once they’re back in the US.